LIXTE Biotechnology Holdings to Present at Two Investor Conferences
Rhea-AI Summary
LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced its participation in two upcoming investor conferences. The company will present at the Investor Summit Summer 2024 Virtual Conference on August 20, 2024, at 2 p.m. EDT, and the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024.
CEO Bas van der Baan will provide an overview of LIXTE's clinical trials with LB-100, their proprietary compound designed to enhance chemotherapy and immunotherapy treatments for cancer. The company is currently conducting proof-of-concept clinical trials for colorectal, ovarian, and sarcoma cancers, including trials funded by GSK and Roche.
Investors can access the presentations through LIXTE's investor relations website and the H.C. Wainwright conference registration page.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LIXT declined 3.33%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference;
and September 9-11 at H.C. Wainwright 26th Annual Global Investment Conference-
PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences:
- The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/11 a.m. PDT. To access the presentation, visit LIXTE’s investor relations website at https://ir.lixte.com/news-events/ir-calendar.
- The H.C. Wainwright 26th Annual Global Investor Conference, on demand starting at 7 a.m. EDT/4 a.m. PDT, September 9-11, 2024. To access the virtual presentation, register for the conference at www.hcwevents.com/annualconference.
Bas van der Baan, CEO of LIXTE, will present an overview of the Company’s clinical trials with LB-100, its proprietary compound focused on enhancing chemotherapy and immunotherapy treatments as cancer therapies. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers, including trials funded by GSK and Roche.
About LIXTE Biotechnology Holdings
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found at www.lixte.com.
For more information about LIXTE, Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations
pwinvestor@pondel.com
Roger Pondel: (310) 279-5965
Laurie Berman: (310) 279-5962
# # #
FAQ
When is LIXTE Biotechnology Holdings (LIXT) presenting at the Investor Summit Summer 2024 Virtual Conference?
What is the date range for LIXTE Biotechnology's (LIXT) presentation at the H.C. Wainwright 26th Annual Global Investment Conference?
What types of cancer is LIXTE Biotechnology (LIXT) currently conducting clinical trials for with LB-100?
Which pharmaceutical companies are funding some of LIXTE Biotechnology's (LIXT) clinical trials?
